Multi-biomarker Risk Score Predicts Complex Revascularization

The findings provide insight into the relationship between cardiovascular biomarkers, coronary anatomical complexity, and incident clinical events.

Related Keywords

Boston ,Massachusetts ,United States ,Paris ,France General ,France ,Coll Cardiol ,Brian Bergmark ,Giles Montalescot ,Zora Biosciences ,Amgen ,Boehringer Ingelheim ,Novartis ,Pfizer ,Astrazeneca ,Journal Of The American College Cardiology ,Bayer Healthcare Pharmaceuticals ,Bristol Myers Squibb ,Quark Pharmaceuticals ,Regeneron Pharmaceuticals ,Medicines Company ,Study Group ,Boston Scientific ,Harvard Medical School ,Philips ,Medtronic ,American College ,Anthos Therapeutics ,Siemens Healthcare Diagnostics ,Abbott Vascular ,Quantum Genomics ,Cv ,Ardiovascular ,Biomarker ,Iological Marker ,Acute Coronary Syndrome Acs ,Cute Coronary Syndrome ,Cs ,Atherosclerotic Heart Disease ,Therosclerotic Cardiovascular Disease ,Oronary Heart Disease ,Schemic Heart Disease ,Coronary Atherosclerosis ,Lipids ,Ipid Management ,Heart Failure , ,Hypertension ,Myocardial Infarction ,Revascularization Procedures In Coronary Artery Disease ,Revascularization ,